Nurse NCPD

23rd Annual School of Breast Oncology® Curriculum

Joyce O’Shaughnessy, MD

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma - Learning Hub

Stay up to date with the latest advances in hematologic malignancies throug…

School of Breast Oncology® (SOBO) Slide & Lecture Library

Joyce O’Shaughnessy, MD

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD;…

Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Ashley S. Margol, MD, M…

Cases and Conversations™: Redefining Treatment Pathways in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD; David M. Gershenson, MD; Ursula Matulonis, MD; David…

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Seth A. Wander, MD, PhD; Yang Liu, MD

Community Practice Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma

Lori A. Leslie, MD; Krish Patel, MD

From Numbers to Navigation: Translating Data From Diabetes Technologies into Optimized Decision-Making

Diana Isaacs, PharmD, BCACP, CDCES, BC-ADM, FADCES, FCCP; Robert H. Eckel, …

Live Tumor Board: Multidisciplinary Strategies to Prevent and Manage ADC-Associated Pulmonary Toxicities in Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; Rachel N. Grisham, MD; Rohit Gupta, MD; M…

From Data to Decisions: Applying the Latest Evidence for New Targeted Therapies in HER2-Positive Gastroesophageal Adenocarcinoma

Pashtoon Kasi, MD, MS; Elizabeth Conner, MD; Simona De Michele, MD

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

June 15, 2026

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Rheumatology Winter Clinical Symposium 2027

February 10-13, 2027

Cases and Conversations™: Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders

June 23, 2026

Oncology Town Hall: Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

June 8, 2026

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD

Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, Maintenance, and Beyond! – Arizona

Naval G. Daver, MD; Matthew Ulrickson, MD

Rhode Island Oncology Society

3 Sessions are Available!

Optimizing HER2 Testing in Gastroesophageal Adenocarcinoma: Laying the Foundation for Targeted Therapy

Yelena Y. Janjigian, MD; Michal F. Segal, BSN, OCN

Show Me the Data®: Evolving Standards and New Frontiers in Ovarian Cancer

Ursula A. Matulonis, MD; Bradley J. Monk, MD, FACS, FACOG; Ritu Salani, MD,…

11th Annual School of Gastrointestinal Oncology®

E. Gabriela Chiorean, MD; Anthony El-Khoueiry, MD

Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice

Eunice Wang, MD; Hetty Carraway, MD, MBA; Naval G. Daver, MD

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, …

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD;…

19th Annual New York GU Cancers Congress®

Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MD

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

4-Part Webinar Series

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, M…

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH

Collaborating Across the Continuum®: Tying the Threads: Screening, Referrals, and Optimized Treatments in MASLD/MASH

Nancy Reau, MD; Conan Tu, MD; Sonal Kumar, MD, MPH

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

Rebecca Shatsky, MD; Maxwell Roger Lloyd, MD; Sarah Sammons, MD; Sherry She…

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

Michael Levy, MD, PhD; Jeffrey L. Bennett, MD, PhD; Eoin P. Flanagan, MB, B…

Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Neil M. Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; Wassim Mchayleh, MD, …

Medical Crossfire®: Translating Risk into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

Ann H. Partridge, MD, MPH; William J. Gradishar, MD, FASCO, FACP; Saranya C…

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, M…

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, …

Show Me the Data™: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

Reshma L. Mahtani, DO; Kamel Abou Hussein, MD; Irene Kang, MD

Obesity: New and Emerging Strategies to Optimally Manage a Chronic Disease

June 5, 2026

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; …

Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies

Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; Priyanka Sharma, MD, FASCO

Medical Crossfire®: Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, …

Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

Naval Daver, MD; Courtney DiNardo, MD; Eunice Wang, MD

Current and Future Directions in Precision-Based ALL Therapy

Elias Jabbour, MD; Hagop M. Kantarjian, MD; Aaron C. Logan, MD, PhD, MPhil